Skip to main content
Top
Published in: Intensive Care Medicine 7/2009

01-07-2009 | Experimental

Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock

Authors: Sebastian Rehberg, Christian Ertmer, Gabriele Köhler, Hans-Ulrich Spiegel, Andrea Morelli, Matthias Lange, Katharina Moll, Katrin Schlack, Hugo Van Aken, Fuhong Su, Jean-Louis Vincent, Martin Westphal

Published in: Intensive Care Medicine | Issue 7/2009

Login to get access

Abstract

Purpose

To compare the effects of first-line therapy with low-dose arginine vasopressin (AVP) or terlipressin (TP) on mesenteric blood flow, plasma AVP levels, organ function and mortality in ovine septic shock.

Methods

Twenty-four adult ewes were anesthetized and instrumented for chronic hemodynamic monitoring. A flow-probe was placed around the superior mesenteric artery, and feces were extracted from the cecum. Following baseline measurements, feces were injected into the peritoneal cavity. When mean arterial pressure (MAP) decreased to less than 60 mmHg, animals were randomly assigned to receive AVP (0.5 mU kg−1 min−1), TP (1 μg kg−1 h−1) or saline (n = 8 each). A norepinephrine infusion was titrated to maintain MAP at 70 ± 5 mmHg in all groups.

Results

Cardiovascular pressures, cardiac output, mesenteric blood flow, and lung tissue concentrations of 3-nitrotyrosine and hemoxygenase-1 were similar among groups throughout the study period. TP infusion resulted in lower plasma AVP concentrations, reduced positive net fluid balance, increased central venous oxygen saturation and slightly prolonged survival compared to control and AVP-treated animals. However, TP treatment was associated with higher liver transaminases and lactate dehydrogenase versus control animals after 12 h.

Conclusions

This study provides evidence that the effects of low-dose TP differ from those of AVP, not only as TP has a longer half life, but also because of different mechanisms of action. Although low-dose TP infusion may be superior to sole norepinephrine or AVP therapy in septic shock, the safety of this therapeutic approach should be determined in more detail.
Appendix
Available only for authorised users
Literature
1.
go back to reference Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618PubMedCrossRef Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618PubMedCrossRef
2.
go back to reference Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time. Crit Care Med 26:2078–2086PubMedCrossRef Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time. Crit Care Med 26:2078–2086PubMedCrossRef
3.
go back to reference Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRef Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRef
4.
5.
go back to reference Duranteau J, Sitbon P, Teboul JL, Vicaut E, Anguel N, Richard C, Samii K (1999) Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 27:893–900PubMedCrossRef Duranteau J, Sitbon P, Teboul JL, Vicaut E, Anguel N, Richard C, Samii K (1999) Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 27:893–900PubMedCrossRef
6.
go back to reference Sun Q, Dimopoulos G, Nguyen DN, Tu Z, Nagy N, Hoang AD, Rogiers P, De Backer D, Vincent JL (2003) Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 168:481–486PubMedCrossRef Sun Q, Dimopoulos G, Nguyen DN, Tu Z, Nagy N, Hoang AD, Rogiers P, De Backer D, Vincent JL (2003) Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 168:481–486PubMedCrossRef
7.
go back to reference Russell J, Walley K, Singer J, Gordon A, Hébert P, Cooper D, Holmes C, Mehta S, Granton J, Storms M, Cook D, Presneill J, Ayers D (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887PubMedCrossRef Russell J, Walley K, Singer J, Gordon A, Hébert P, Cooper D, Holmes C, Mehta S, Granton J, Storms M, Cook D, Presneill J, Ayers D (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887PubMedCrossRef
8.
go back to reference Pesaturo AB, Jennings HR, Voils SA (2006) Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 40:2170–2177PubMedCrossRef Pesaturo AB, Jennings HR, Voils SA (2006) Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 40:2170–2177PubMedCrossRef
9.
go back to reference Leone M, Martin C (2006) Rescue therapy in septic shock—is terlipressin the last frontier? Crit Care 10:131PubMedCrossRef Leone M, Martin C (2006) Rescue therapy in septic shock—is terlipressin the last frontier? Crit Care 10:131PubMedCrossRef
10.
go back to reference Michel F, Thomachot L, David M, Nicaise C, Vialet R, Di Marco JN, Lagier P, Martin C (2007) Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. Am J Emerg Med 25:863 e861–862PubMedCrossRef Michel F, Thomachot L, David M, Nicaise C, Vialet R, Di Marco JN, Lagier P, Martin C (2007) Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. Am J Emerg Med 25:863 e861–862PubMedCrossRef
11.
go back to reference Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Bone HG, Van Aken H, Traber DL, Westphal M (2007) Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28:623–629PubMedCrossRef Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Bone HG, Van Aken H, Traber DL, Westphal M (2007) Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28:623–629PubMedCrossRef
12.
go back to reference Bernadich C, Bandi JC, Melin P, Bosch J (1998) Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 27:351–356PubMedCrossRef Bernadich C, Bandi JC, Melin P, Bosch J (1998) Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 27:351–356PubMedCrossRef
13.
go back to reference Rehberg S, Ertmer C, Lange M, Pinto B, Morelli A, Van Aken H, Su F, Vincent J, Westphal M (2008) Vasopressin and terlipressin as first-line therapy in fulminant ovine septic shock. Crit Care 12:P405CrossRef Rehberg S, Ertmer C, Lange M, Pinto B, Morelli A, Van Aken H, Su F, Vincent J, Westphal M (2008) Vasopressin and terlipressin as first-line therapy in fulminant ovine septic shock. Crit Care 12:P405CrossRef
14.
go back to reference Su F, Nguyen ND, Creteur J, Cai Y, Nagy N, Anh-Dung H, Amaral A, Bruzzi de Carvalho F, Chochrad D, Vincent JL (2004) Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury. Shock 22:145–150PubMedCrossRef Su F, Nguyen ND, Creteur J, Cai Y, Nagy N, Anh-Dung H, Amaral A, Bruzzi de Carvalho F, Chochrad D, Vincent JL (2004) Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury. Shock 22:145–150PubMedCrossRef
15.
go back to reference Wang Z, Su F, Rogiers P, Vincent JL (2007) Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 35:2594–2600PubMedCrossRef Wang Z, Su F, Rogiers P, Vincent JL (2007) Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 35:2594–2600PubMedCrossRef
16.
go back to reference Su F, Wang Z, Cai Y, Rogiers P, Vincent JL (2007) Fluid resuscitation in severe sepsis and septic shock: albumin, hydroxyethyl starch, gelatin or ringer’s lactate-does it really make a difference? Shock 27:520–526PubMedCrossRef Su F, Wang Z, Cai Y, Rogiers P, Vincent JL (2007) Fluid resuscitation in severe sepsis and septic shock: albumin, hydroxyethyl starch, gelatin or ringer’s lactate-does it really make a difference? Shock 27:520–526PubMedCrossRef
17.
go back to reference Su F, Wang Z, Cai Y, Remmelink M, Vincent JL (2007) Beneficial effects of ethyl pyruvate in septic shock from peritonitis. Arch Surg 142:166–171PubMedCrossRef Su F, Wang Z, Cai Y, Remmelink M, Vincent JL (2007) Beneficial effects of ethyl pyruvate in septic shock from peritonitis. Arch Surg 142:166–171PubMedCrossRef
18.
go back to reference Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, Herndon DN, Schmalstieg FC, Traber DL, Hawkins HK (2003) Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol 29:295–302PubMedCrossRef Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, Herndon DN, Schmalstieg FC, Traber DL, Hawkins HK (2003) Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol 29:295–302PubMedCrossRef
19.
go back to reference Westphal M, Cox RA, Traber LD, Morita N, Enkhbaatar P, Schmalstieg FC, Hawkins HK, Maybauer DM, Maybauer MO, Murakami K, Burke AS, Westphal-Varghese BB, Rudloff HE, Salsbury JR, Jodoin JM, Lee S, Traber DL (2006) Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction. Crit Care Med 34:1428–1436PubMedCrossRef Westphal M, Cox RA, Traber LD, Morita N, Enkhbaatar P, Schmalstieg FC, Hawkins HK, Maybauer DM, Maybauer MO, Murakami K, Burke AS, Westphal-Varghese BB, Rudloff HE, Salsbury JR, Jodoin JM, Lee S, Traber DL (2006) Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction. Crit Care Med 34:1428–1436PubMedCrossRef
20.
go back to reference Westphal M, Enkhbaatar P, Schmalstieg FC, Kulp GA, Traber LD, Morita N, Cox RA, Hawkins HK, Westphal-Varghese BB, Rudloff HE, Maybauer DM, Maybauer MO, Burke AS, Murakami K, Saunders F, Horvath EM, Szabo C, Traber DL (2008) Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep. Crit Care Med 36:1196–1204PubMedCrossRef Westphal M, Enkhbaatar P, Schmalstieg FC, Kulp GA, Traber LD, Morita N, Cox RA, Hawkins HK, Westphal-Varghese BB, Rudloff HE, Maybauer DM, Maybauer MO, Burke AS, Murakami K, Saunders F, Horvath EM, Szabo C, Traber DL (2008) Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep. Crit Care Med 36:1196–1204PubMedCrossRef
21.
22.
23.
go back to reference Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M (2008) Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin Exp Rheumatol 26:373–378PubMed Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M (2008) Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin Exp Rheumatol 26:373–378PubMed
24.
go back to reference Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M (2006) Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med 34:3005–3010PubMed Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M (2006) Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med 34:3005–3010PubMed
25.
go back to reference Czabanka M, Peter C, Martin E, Walther A (2007) Microcirculatory endothelial dysfunction during endotoxemia—insights into pathophysiology, pathologic mechanisms and clinical relevance. Curr Vasc Pharmacol 5:266–275PubMedCrossRef Czabanka M, Peter C, Martin E, Walther A (2007) Microcirculatory endothelial dysfunction during endotoxemia—insights into pathophysiology, pathologic mechanisms and clinical relevance. Curr Vasc Pharmacol 5:266–275PubMedCrossRef
26.
go back to reference Traber D (2007) Selective V1a receptor agonists in experimental septic shock [Abstract]. Crit Care 11:P51CrossRef Traber D (2007) Selective V1a receptor agonists in experimental septic shock [Abstract]. Crit Care 11:P51CrossRef
27.
go back to reference Laporte R, Wisniewska H, Callejas L, Russell J, Landry D, Rivière P (2008) The selective V1a receptor agonist FE 202158 reverses platelet activating factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Shock Suppl 1, P21 Laporte R, Wisniewska H, Callejas L, Russell J, Landry D, Rivière P (2008) The selective V1a receptor agonist FE 202158 reverses platelet activating factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Shock Suppl 1, P21
28.
go back to reference O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210PubMedCrossRef O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210PubMedCrossRef
29.
go back to reference Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319PubMedCrossRef Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319PubMedCrossRef
30.
go back to reference Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582PubMedCrossRef Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582PubMedCrossRef
31.
go back to reference Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659–2666PubMedCrossRef Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659–2666PubMedCrossRef
32.
33.
go back to reference Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703 discussion 703–695PubMedCrossRef Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703 discussion 703–695PubMedCrossRef
34.
go back to reference Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P (2004) Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597–604PubMedCrossRef Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P (2004) Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597–604PubMedCrossRef
35.
go back to reference Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902PubMedCrossRef Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902PubMedCrossRef
36.
go back to reference Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C (2004) Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314–319PubMedCrossRef Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C (2004) Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314–319PubMedCrossRef
37.
go back to reference Booke M, Hinder F, McGuire R, Traber LD, Traber DL (1996) Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow. Shock 5:362–370PubMedCrossRef Booke M, Hinder F, McGuire R, Traber LD, Traber DL (1996) Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow. Shock 5:362–370PubMedCrossRef
38.
go back to reference Lange M, Broking K, Hucklenbruch C, Ertmer C, Van Aken H, Lucke M, Bone HG, Westphal M (2007) Hemodynamic effects of titrated norepinephrine in healthy versus endotoxemic sheep. J Endotoxin Res 13:53–57PubMedCrossRef Lange M, Broking K, Hucklenbruch C, Ertmer C, Van Aken H, Lucke M, Bone HG, Westphal M (2007) Hemodynamic effects of titrated norepinephrine in healthy versus endotoxemic sheep. J Endotoxin Res 13:53–57PubMedCrossRef
39.
go back to reference Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394–1398PubMedCrossRef Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394–1398PubMedCrossRef
40.
go back to reference Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E (2003) The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 97:1756–1763PubMedCrossRef Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E (2003) The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 97:1756–1763PubMedCrossRef
41.
go back to reference Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646–2650PubMedCrossRef Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646–2650PubMedCrossRef
42.
go back to reference Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756–1760PubMedCrossRef Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756–1760PubMedCrossRef
43.
go back to reference Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421PubMedCrossRef Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421PubMedCrossRef
44.
go back to reference Landry DW, Levin HR, Gallant EM, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282PubMedCrossRef Landry DW, Levin HR, Gallant EM, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282PubMedCrossRef
45.
go back to reference Asfar P, Hauser B, Ivanyi Z, Ehrmann U, Kick J, Albicini M, Vogt J, Wachter U, Bruckner UB, Radermacher P, Bracht H (2005) Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 33:373–380PubMedCrossRef Asfar P, Hauser B, Ivanyi Z, Ehrmann U, Kick J, Albicini M, Vogt J, Wachter U, Bruckner UB, Radermacher P, Bracht H (2005) Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 33:373–380PubMedCrossRef
46.
go back to reference Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215–220PubMedCrossRef Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215–220PubMedCrossRef
47.
go back to reference Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB, Rodriguez-Nunez A (2006) Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 68:151–153PubMedCrossRef Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB, Rodriguez-Nunez A (2006) Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 68:151–153PubMedCrossRef
48.
go back to reference Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C (2006) Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 10:R20PubMedCrossRef Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C (2006) Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 10:R20PubMedCrossRef
49.
go back to reference Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125PubMed Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125PubMed
50.
go back to reference Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758PubMedCrossRef Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758PubMedCrossRef
51.
go back to reference Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW (2004) Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 32:194–200PubMedCrossRef Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW (2004) Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 32:194–200PubMedCrossRef
53.
go back to reference Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493PubMedCrossRef Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493PubMedCrossRef
54.
go back to reference Van Tol HH, Kiss JZ, Burbach JP (1989) Differential responses in vasopressin and oxytocin gene expression in distinct hypothalamic nuclei after hypothalamoneurohypophyseal disconnection and vasopressin substitution. Neuroendocrinology 49:337–343PubMedCrossRef Van Tol HH, Kiss JZ, Burbach JP (1989) Differential responses in vasopressin and oxytocin gene expression in distinct hypothalamic nuclei after hypothalamoneurohypophyseal disconnection and vasopressin substitution. Neuroendocrinology 49:337–343PubMedCrossRef
55.
go back to reference Naylor AM, Cooper KE, Veale WL (1987) Vasopressin and fever: evidence supporting the existence of an endogenous antipyretic system in the brain. Can J Physiol Pharmacol 65:1333–1338PubMed Naylor AM, Cooper KE, Veale WL (1987) Vasopressin and fever: evidence supporting the existence of an endogenous antipyretic system in the brain. Can J Physiol Pharmacol 65:1333–1338PubMed
56.
go back to reference Zhao L, Brinton RD (2004) Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 24:2226–2235PubMedCrossRef Zhao L, Brinton RD (2004) Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 24:2226–2235PubMedCrossRef
57.
go back to reference Radi R (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 101:4003–4008PubMedCrossRef Radi R (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 101:4003–4008PubMedCrossRef
58.
go back to reference Chung SW, Liu X, Macias AA, Baron RM, Perrella MA (2008) Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J Clin Invest 118:239–247PubMedCrossRef Chung SW, Liu X, Macias AA, Baron RM, Perrella MA (2008) Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J Clin Invest 118:239–247PubMedCrossRef
Metadata
Title
Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock
Authors
Sebastian Rehberg
Christian Ertmer
Gabriele Köhler
Hans-Ulrich Spiegel
Andrea Morelli
Matthias Lange
Katharina Moll
Katrin Schlack
Hugo Van Aken
Fuhong Su
Jean-Louis Vincent
Martin Westphal
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 7/2009
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-009-1470-z

Other articles of this Issue 7/2009

Intensive Care Medicine 7/2009 Go to the issue